These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 30069768)

  • 1. Lenvantinib: A Tyrosine Kinase Inhibitor of VEGFR 1-3, FGFR 1-4, PDGFRα, KIT and RET.
    Zschäbitz S; Grüllich C
    Recent Results Cancer Res; 2018; 211():187-198. PubMed ID: 30069768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lenvatinib: Role in thyroid cancer and other solid tumors.
    Cabanillas ME; Habra MA
    Cancer Treat Rev; 2016 Jan; 42():47-55. PubMed ID: 26678514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lenvatinib: A Promising Molecular Targeted Agent for Multiple Cancers.
    Suyama K; Iwase H
    Cancer Control; 2018; 25(1):1073274818789361. PubMed ID: 30032643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models.
    Okamoto K; Kodama K; Takase K; Sugi NH; Yamamoto Y; Iwata M; Tsuruoka A
    Cancer Lett; 2013 Oct; 340(1):97-103. PubMed ID: 23856031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Pharmacokinetic and Pharmacodynamic Profile of Lenvatinib, an Orally Active, Small-Molecule, Multitargeted Tyrosine Kinase Inhibitor.
    Hussein Z; Mizuo H; Hayato S; Namiki M; Shumaker R
    Eur J Drug Metab Pharmacokinet; 2017 Dec; 42(6):903-914. PubMed ID: 28236116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New insights into the mechanism of resistance to lenvatinib and strategies for lenvatinib sensitization in hepatocellular carcinoma.
    Fan FM; Fleishman JS; Chen J; Chen ZS; Dong HH
    Drug Discov Today; 2024 Aug; 29(8):104069. PubMed ID: 38936692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer.
    Cabanillas ME; Takahashi S
    Semin Oncol; 2019 Feb; 46(1):57-64. PubMed ID: 30685073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The action and resistance mechanisms of Lenvatinib in liver cancer.
    Buttell A; Qiu W
    Mol Carcinog; 2023 Dec; 62(12):1918-1934. PubMed ID: 37671815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological and clinical profile of lenvatinib (E-7080) in the treatment of advanced, radioiodine-refractory, differentiated thyroid cancer.
    Hegazi M; Azadi A; Jain D; Redman R; Perez CA
    Drugs Today (Barc); 2015 Dec; 51(12):689-94. PubMed ID: 26798849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lenvatinib as a therapy for unresectable hepatocellular carcinoma.
    Spallanzani A; Orsi G; Andrikou K; Gelsomino F; Rimini M; Riggi L; Cascinu S
    Expert Rev Anticancer Ther; 2018 Nov; 18(11):1069-1076. PubMed ID: 30220234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lenvatinib: A Review in Refractory Thyroid Cancer.
    Frampton JE
    Target Oncol; 2016 Feb; 11(1):115-22. PubMed ID: 26867945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lenvatinib in the Therapy of Aggressive Thyroid Cancer: State of the Art and New Perspectives with Patents Recently Applied.
    Ferrari SM; Ruffilli I; Centanni M; Virili C; Materazzi G; Alexopoulou M; Miccoli M; Antonelli A; Fallahi P
    Recent Pat Anticancer Drug Discov; 2018; 13(2):201-208. PubMed ID: 29468981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment-emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT).
    Wirth LJ; Tahara M; Robinson B; Francis S; Brose MS; Habra MA; Newbold K; Kiyota N; Dutcus CE; Mathias E; Guo M; Sherman SI; Schlumberger M
    Cancer; 2018 Jun; 124(11):2365-2372. PubMed ID: 29656442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lenvatinib for the treatment of renal cell carcinoma.
    Roviello G; Corona SP; Bozza G; Aieta M; Generali D; Rodriquenz MG; Mileo AM; Imperatori M; Ianza A; Conca R; Sobhani N
    Expert Opin Investig Drugs; 2018 May; 27(5):507-512. PubMed ID: 29718721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model.
    Kimura T; Kato Y; Ozawa Y; Kodama K; Ito J; Ichikawa K; Yamada K; Hori Y; Tabata K; Takase K; Matsui J; Funahashi Y; Nomoto K
    Cancer Sci; 2018 Dec; 109(12):3993-4002. PubMed ID: 30447042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetic-pharmacodynamic modeling of serum biomarkers as predictors of tumor dynamics following lenvatinib treatment in patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC).
    Majid O; Hayato S; Sreerama Reddy SH; Lalovic B; Hihara T; Hoshi T; Funahashi Y; Aluri J; Takenaka O; Yasuda S; Hussein Z
    CPT Pharmacometrics Syst Pharmacol; 2024 Jun; 13(6):954-969. PubMed ID: 38528813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multitargeting strategy using lenvatinib and golvatinib: maximizing anti-angiogenesis activity in a preclinical cancer model.
    Nakazawa Y; Kawano S; Matsui J; Funahashi Y; Tohyama O; Muto H; Nakagawa T; Matsushima T
    Cancer Sci; 2015 Feb; 106(2):201-7. PubMed ID: 25458359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lenvatinib in combination with golvatinib overcomes hepatocyte growth factor pathway-induced resistance to vascular endothelial growth factor receptor inhibitor.
    Nakagawa T; Matsushima T; Kawano S; Nakazawa Y; Kato Y; Adachi Y; Abe T; Semba T; Yokoi A; Matsui J; Tsuruoka A; Funahashi Y
    Cancer Sci; 2014 Jun; 105(6):723-30. PubMed ID: 24689876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Lenvatinib in radioiodine refractory thyroid carcinomas].
    de la Fouchardiere C
    Bull Cancer; 2016 Nov; 103(11):905-910. PubMed ID: 27817859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lenvatinib: first global approval.
    Scott LJ
    Drugs; 2015 Apr; 75(5):553-60. PubMed ID: 25795101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.